You have accessJournal of UrologyProstate Cancer: Localized III1 Apr 2012691 PROGNOSTIC PREDICTORS IN PROSTATE CANCER CASES WITH BIOCHEMICAL PROGRESSION AFTER SURGERY TREATED WITH INTERMITTENT ANDROGEN DEPRIVATION (IAD) Alessandro Sciarra, Susanna Cattarino, Stefano Salciccia, Alessandro Gentilucci, Andrea Alfarone, Michele Innocenzi, Francesco Minisola, and Vincenzo Gentile Alessandro SciarraAlessandro Sciarra Rome, Italy More articles by this author , Susanna CattarinoSusanna Cattarino Rome, Italy More articles by this author , Stefano SalcicciaStefano Salciccia Rome, Italy More articles by this author , Alessandro GentilucciAlessandro Gentilucci Rome, Italy More articles by this author , Andrea AlfaroneAndrea Alfarone Rome, Italy More articles by this author , Michele InnocenziMichele Innocenzi Rome, Italy More articles by this author , Francesco MinisolaFrancesco Minisola Rome, Italy More articles by this author , and Vincenzo GentileVincenzo Gentile Rome, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.774AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To define characteristics of the first cycle of IAD that would predict for outcomes in a long term follow-up.The end-points of the trial was time to clinical progression(CP)and time to castration resistance PC(CRPC). METHODS Eighty-four cases were included in the study. In all cases, after an initial induction period, an acceptable nadir to switch from on-to-off-phase of IAD was considered to be a serum PSA of less than 1.0 ng/ml. As possible predictors for time to CP and CRPC we analyzed pretreatment parameters such as age,Gleason Score,serum PSA,testosterone and Chromogranina A(CgA)levels and characteristics from the first cycle of IAD. RESULTS Mean follow-up during IAD was 88.69±16.74 months;29.77% of patients developed CRPC and 14.28% of cases showed a CP with a mean time of 88.40±14.34 months and 106.50±20.65 months respectively.At the univariate and multivariate analysis the PSA nadir during the first on-phase period and the first off-phase interval resulted significant and independent predictors(p<0.001)of the time to CRPC and CP.In particular for cases with a PSA nadir >0.4 ng/ml and for those with an off-phase interval≤24 weeks,the risk of CRPC and CP during IAD was 2.7-2.5 and 3.0-3.1 times that for patients with a PSA nadir≤0.1 ng/ml and with an off-phase interval>48 weeks respectively. CONCLUSIONS Cases with BP after RP selected to IAD that show at the first cycle a PSA nadir≤0.1 ng/ml and a off-phase interval≥48 weeks, are the best candidate for long IAD treatments without the development of CRPC or CP. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e282 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alessandro Sciarra Rome, Italy More articles by this author Susanna Cattarino Rome, Italy More articles by this author Stefano Salciccia Rome, Italy More articles by this author Alessandro Gentilucci Rome, Italy More articles by this author Andrea Alfarone Rome, Italy More articles by this author Michele Innocenzi Rome, Italy More articles by this author Francesco Minisola Rome, Italy More articles by this author Vincenzo Gentile Rome, Italy More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...